The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
Open Access
Abstract
Botulinum neurotoxin (BoNT) can counteract the highly frequent involuntary muscle contractions and the uncontrolled micturition events that characterize the neurogenic detrusor overactivity (NDO) due to supra-sacral spinal cord lesions. The ability of the toxin to block the neurotransmitter vesicular release causes the reduction of contractions and improves the compliance of the muscle and the bladder filling. BoNT is the second-choice treatment for NDO once the anti-muscarinic drugs have lost their effects. However, the toxin shows a time-dependent efficacy reduction up to a complete loss of activity. The cellular mechanisms responsible for BoNT effects exhaustion are not yet completely defined. Similarly, also the sites of its action are still under identification. A growing amount of data suggest that BoNT, beyond the effects on the efferent terminals, would act on the sensory system recently described in the bladder mucosa. The specimens from NDO patients no longer responding to BoNT treatment displayed a significant increase of the afferent terminals, likely excitatory, and signs of a chronic neurogenic inflammation in the mucosa. In summary, beyond the undoubted benefits in ameliorating the NDO symptomatology, BoNT treatment might bring to alterations in the bladder sensory system able to shorten its own effectiveness.Keywords
Funding Information
- AOUC (Azienda Ospedaliera Universitaria Careggi) Florence (AOUC ric.41 – 2011)
This publication has 85 references indexed in Scilit:
- Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinicsSpinal Cord, 2013
- Clinical Uses of Botulinum Neurotoxins: Current Indications, Limitations and Future DevelopmentsToxins, 2012
- The Health and Life Priorities of Individuals with Spinal Cord Injury: A Systematic ReviewJournal of Neurotrauma, 2012
- Modulation of bladder myofibroblast activity: implications for bladder functionAmerican Journal of Physiology-Renal Physiology, 2008
- Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin AThe Journal of Physiology, 2008
- Drug Insight: biological effects of botulinum toxin A in the lower urinary tractNature Reviews Endocrinology, 2008
- Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injuryNeurochemistry International, 2008
- Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammationBJU International, 2008
- Non-neuronal acetylcholine and urinary bladder urotheliumLife Sciences, 2007
- INHIBITORY EFFECT OF INTRAVESICALLY APPLIED BOTULINUM TOXIN A IN CHRONIC BLADDER INFLAMMATIONJournal of Urology, 2005